Details of the Drug
General Information of Drug (ID: DMTDB62)
Drug Name |
3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; 65347-55-9; 38620-69-8; MLS000093715; SMR000029333; CHEMBL27811; 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole; 3-(4-1,2,5,6-tetrahydropyridyl)indole; THPindole; ChemDiv2_002931; AC1Q1GX4; SCHEMBL653742; AC1MC402; CTK5C2597; cid_2761023; BDBM31023; DTXSID20375484; CIRSPTXGPFAXRE-UHFFFAOYSA-N; MolPort-000-159-541; HMS1377F05; ZINC154399; STK801496; 2202AE; SBB092334; BBL010213; MFCD03695471; AKOS000505683; FS-1743; NE12559; CCG-139909
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 198.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||